OraSure Technologies (OSUR) Stock Analysis & Winston Score

OraSure Technologies makes medical testing products that collect samples from saliva, oral fluid, or fingersticks instead of drawing blood. Its best-known products include at-home HIV tests (the OraQuick brand) and oral fluid collection devices used by labs, employers, and public health agencies for drug testing and disease screening. The company also sells molecular collection kits used in genetic research and diagnostics. OraSure earns revenue by selling its testing devices and collection kits to hospitals, clinics, government health programs, and research organizations, primarily in the United States but also internationally. The OraQuick HIV test holds a strong position as the only FDA-approved over-the-counter HIV self-test in the US, which gives it a niche competitive advantage. However, the company has been losing money at the operating level, and its main risk is that COVID-related testing demand has faded sharply, leaving it dependent on slower-growing core markets like HIV testing and molecular collection while it works to return to profitability.